Literature DB >> 15742106

Current treatments in neurology: stroke.

Hugh S Markus1.   

Abstract

There have been major advances in stroke treatment based on robust evidence from large clinical trials. This review covers both acute treatment and secondary prevention. Thrombolysis is now established as a therapy for ischaemic stroke presenting within 3 hours, and the possibility of extending the time window and refining the selection of suitable patients, is being addressed in further trials. Anticoagulants are of proven benefit in cardioembolic stroke, and particularly atrial fibrillation. For prevention of other stroke subtypes antiplatelet agents appear to have a better risk-benefit ratio. Evidence for the use of dual antiplatelet therapy, including the recent MATCH study, are discussed. Carotid endarterectomy is of proven benefit in patients with>70% symptomatic stenosis. Recent analysis has emphasised the importance of operating as soon after symptom onset as possible. Operating on asymptomatic carotid stenosis remains controversial; even after the recent Asymptomatic Carotid Surgery Trial which showed that by operating on 32 people one disabling stroke or death could be prevented over a 5 years period.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742106     DOI: 10.1007/s00415-005-0736-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  41 in total

Review 1.  Where is the evidence that animal research benefits humans?

Authors:  Pandora Pound; Shah Ebrahim; Peter Sandercock; Michael B Bracken; Ian Roberts
Journal:  BMJ       Date:  2004-02-28

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial.

Authors: 
Journal:  Lancet       Date:  2001-06-02       Impact factor: 79.321

4.  A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1997-12       Impact factor: 10.422

5.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

Review 6.  Organised inpatient (stroke unit) care for stroke.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2002

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial.

Authors:  A Halliday; A Mansfield; J Marro; C Peto; R Peto; J Potter; D Thomas
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

10.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

View more
  1 in total

1.  Cilostazol reduces PAC-1 expression on platelets in ischemic stroke.

Authors:  Su-Yun Lee; Myong-Jin Kang; Jae-Kwan Cha
Journal:  J Clin Neurol       Date:  2008-12-31       Impact factor: 3.077

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.